CVRx to Present at the William Blair 45th Annual Growth Stock Conference
CVRx (NASDAQ: CVRX), a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular diseases, has announced its participation in the William Blair 45th Annual Growth Stock Conference. The company's management team is scheduled to present on June 4, 2025, at 10:00am Central Time. Investors and interested parties can access the live audio webcast of the presentation through the investor relations section of CVRx's website at ir.cvrx.com.
CVRx (NASDAQ: CVRX), un'azienda di dispositivi medici in fase commerciale specializzata in soluzioni di neuromodulazione per le malattie cardiovascolari, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale William Blair sulle Azioni in Crescita. Il team di gestione dell'azienda presenterà il 4 giugno 2025 alle 10:00 ora centrale. Investitori e interessati possono seguire la trasmissione audio in diretta della presentazione tramite la sezione relazioni con gli investitori sul sito web di CVRx all'indirizzo ir.cvrx.com.
CVRx (NASDAQ: CVRX), una empresa de dispositivos médicos en etapa comercial especializada en soluciones de neuromodulación para enfermedades cardiovasculares, ha anunciado su participación en la 45ª Conferencia Anual de Acciones de Crecimiento William Blair. El equipo directivo de la empresa tiene programada una presentación el 4 de junio de 2025 a las 10:00 a.m., hora central. Los inversores y las partes interesadas pueden acceder a la transmisión de audio en vivo de la presentación a través de la sección de relaciones con inversores en el sitio web de CVRx en ir.cvrx.com.
CVRx (NASDAQ: CVRX)는 심혈관 질환을 위한 신경 조절 솔루션을 전문으로 하는 상업 단계 의료기기 회사로, William Blair 제45회 연례 성장주 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2025년 6월 4일 오전 10시(중부 시간)에 발표할 예정입니다. 투자자 및 관심 있는 분들은 CVRx 웹사이트의 투자자 관계 섹션(ir.cvrx.com)을 통해 발표의 실시간 오디오 웹캐스트를 시청할 수 있습니다.
CVRx (NASDAQ : CVRX), une entreprise de dispositifs médicaux en phase commerciale spécialisée dans les solutions de neuromodulation pour les maladies cardiovasculaires, a annoncé sa participation à la 45e conférence annuelle William Blair sur les actions de croissance. L'équipe de direction de l'entreprise doit présenter le 4 juin 2025 à 10h00, heure centrale. Les investisseurs et les parties intéressées peuvent accéder à la diffusion audio en direct de la présentation via la section relations investisseurs du site web de CVRx à l'adresse ir.cvrx.com.
CVRx (NASDAQ: CVRX), ein medizinisches Unternehmen in der kommerziellen Phase, das sich auf Neuromodulationslösungen für Herz-Kreislauf-Erkrankungen spezialisiert hat, hat seine Teilnahme an der 45. William Blair Jahreskonferenz für Wachstumsaktien angekündigt. Das Management-Team des Unternehmens wird am 4. Juni 2025 um 10:00 Uhr Central Time präsentieren. Investoren und Interessierte können die Live-Audio-Webcast-Präsentation über den Bereich Investor Relations auf der CVRx-Website unter ir.cvrx.com verfolgen.
- None.
- None.
MINNEAPOLIS, May 28, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025. The Company is scheduled to present at 10:00am Central Time the same day via webcast.
A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com
Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com
FAQ
When is CVRx (CVRX) presenting at the William Blair Growth Stock Conference 2025?
How can I watch CVRx's (CVRX) presentation at the William Blair conference?
What does CVRx (CVRX) company do?
Which stock exchange is CVRx (CVRX) listed on?
